2023-05-26

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use
- Subjects in Herniorrhaphy Study Dosed - Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed SAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs in the peri-operative space, announced it has initiated ...
2022-10-17

Cali Biosciences Announces Publication of Phase IIa Results of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue Models Confirming Pharmacokinetics and Safety
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction: Publication of “CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty” i...
2022-07-27

Cali Biosciences Begins and Immediately Fulfills Initial Enrollment for Long-Acting Ropivacaine (CPL-01) Phase II Trial in Bunionectomy
Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase II bunionectomy study of its peri-operative long-acting ropivacaine product (CPL- 01) for post-operative pain control and opioid reduction through 72 hours after bunionectomy.  In a surprise, all slots in the initial cohort of the trial immediat...
2022-03-21

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting analgesic product CPL-01. CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), deve...
2021-11-19

ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) Meeting. CPL-01 is an extended-release injectable version of ropivacaine hydroc...
2021-08-11

Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its perioperative long-acting analgesic product CPL- 01. CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), developed by CaliBio to treat...